Journal profile · Biochemistry & Molecular Biology
International Journal of Peptide Research and Therapeutics
ISSN 1573-3149 · eISSN 1573-3904 · Springer Netherlands · UNITED STATES · Quarterly · Founded 1994
International Journal of Peptide Research and Therapeutics: CAS Zone 4 · Biology (2025 upgraded edition); impact factor 2.47; hybrid open access; APC about USD 3,890; median 74 days to acceptance (53 articles, last 24 months); community-reported acceptance: easy; 115 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
International Journal of Peptide Research and Therapeutics is published by Springer Netherlands and is in Zone 4 of Biology in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Chemical Synthesis and Analysis, Antimicrobial Peptides and Activities and Protein Hydrolysis and Bioactive Peptides, together about 35.2% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
The International Journal for Peptide Research & Therapeutics is an international, peer-reviewed journal focusing on issues, research, and integration of knowledge on the latest developments in peptide therapeutics. The Journal brings together in a single source the most exciting work in peptide research, including isolation, structural characterization, synthesis and biological activity of peptides, and thereby aids in the development of unifying concepts from diverse perspectives. The Journal invites substantial contributions in the following thematic areas: - New advances in peptide drug delivery systems - Application of peptide therapeutics to specific diseases - New advances in synthetic methods - The development of new procedures for construction of peptide libraries and methodology for screening of such mixtures - The use of peptides in the study of enzyme specificity and mechanism, receptor binding and antibody/antigen interactions - Applications of such techniques as chromatography, electrophoresis, NMR and X-ray crystallography, mass spectrometry Please note that manuscripts that solely describe in silico work that does not include subsequent validating laboratory data will not be considered and will be rejected at the submission stage.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry & Molecular Biology
Editor-in-chief Fernando AlbericioPublisher website
Editorial board by country: 4 in mainland China (about 10%); most named United States 6, Australia 5, Mainland China 4, Japan 3, India 3 (40 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Chemical Synthesis and AnalysisBiochemistry, Genetics and Molecular Biology13.1%
- Antimicrobial Peptides and ActivitiesImmunology and Microbiology12.8%
- Protein Hydrolysis and Bioactive PeptidesBiochemistry, Genetics and Molecular Biology9.4%
- Biochemical and Structural CharacterizationBiochemistry, Genetics and Molecular Biology6.6%
- Monoclonal and Polyclonal Antibodies ResearchMedicine6.1%
- vaccines and immunoinformatics approachesBiochemistry, Genetics and Molecular Biology5.3%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology4.2%
- Neuropeptides and Animal PhysiologyNeuroscience3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Biology Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 4 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Biology Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 3 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Biology Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 4 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCASCAB AbstractsPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.47LetPub ·
- Impact factor (publisher) 2025
- 2.5Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.3Publisher website ·
- CiteScore 2026-06
- 5.3LetPub ·
- SJR 2026-06
- 0.53LetPub ·
- SNIP 2026-06
- 0.62LetPub ·
- h-index
- 30LetPub ·
- h-index
- 58OpenAlex ·
- i10-index
- 759OpenAlex ·
- 2-year mean citedness
- 2.34OpenAlex ·
- Self-citation rate
- 4%LetPub ·
- Share of gold OA articles
- 12.2%LetPub ·
Volume
- Articles per year
- 111LetPub ·
- Downloads per year (publisher) 2025
- 273,500Publisher website ·
Articles by year OpenAlex count · 2,239 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 74 | 16 | 16 |
| 2025 | 115 | 22 | 271 |
| 2024 | 86 | 14 | 357 |
| 2023 | 97 | 26 | 842 |
| 2022 | 141 | 42 | 1,507 |
| 2021 | 192 | 54 | 2,024 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
74 daysMedian, submission to acceptance · P25–P75 54 days – 95 days
- Acceptance to online
- median 19 days (91 articles)
- Submission to online
- median 90 days
- Sample
- 53 articles with submission and acceptance dates (221 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Submission to first decision
- 5 daysPublisher website ·
- Peer review
- Double anonymous peer review, Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,890 / EUR 2,990 / GBP 2,590 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Author–date
- Suggested reviewers
- Optional
Article types accepted6, with length limits
- brief reportResearch article These are substantial, in-depth, novel research studies of interest to the readership of the journal. Review: Review papers should summarize th…main text ≤ 1,500 words · abstract ≤ 80 words
- editorialSingle-blind peer review This journal follows a single-blind reviewing procedure. Peer Review Process All submitted manuscripts are firstly assessed by the Edit…Length not stated
- full articleResearch article These are substantial, in-depth, novel research studies of interest to the readership of the journal. Review: Review papers should summarize th…Length not stated
- hypothesisResearch article These are substantial, in-depth, novel research studies of interest to the readership of the journal. Review: Review papers should summarize th…Length not stated
- research articleResearch article These are substantial, in-depth, novel research studies of interest to the readership of the journal. Review: Review papers should summarize th…Length not stated
- reviewResearch article These are substantial, in-depth, novel research studies of interest to the readership of the journal. Review: Review papers should summarize th…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data availability statements
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in International Journal of Peptide Research and Therapeutics, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review Peer Review Process
Single-blind peer review Model summary
All submitted manuscripts are firstly assessed by the Editors-in-Chief of the journal and secondly, by the associate editors or guest editors (in case the manuscript is submitted to a topical collection). Only those papers that seem to meet our editorial criteria are sent for formal review, typically to two or three reviewers. Reviewers are selected based on their expertise, reputation, specific r…
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Netherlands
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 1994
- ISSN
- 1573-3149
- Electronic ISSN
- 1573-3904
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about International Journal of Peptide Research and Therapeutics
What CAS zone is International Journal of Peptide Research and Therapeutics in?
In the 2025 upgraded edition of the CAS Journal Ranking, International Journal of Peptide Research and Therapeutics is in Zone 4 of Biology, and in Zone 4 of the minor category Biochemistry & Molecular Biology. In the 2026 Xinrui edition it is in Zone 3 of Biology. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of International Journal of Peptide Research and Therapeutics?
The latest impact factor listed by LetPub is 2.47; CiteScore 5.3, h-index 58.
How long does peer review take at International Journal of Peptide Research and Therapeutics?
Based on the dates recorded on 53 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 74 days (interquartile range 54–95 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of International Journal of Peptide Research and Therapeutics?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Author–date; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of International Journal of Peptide Research and Therapeutics based?
Of the 40 board members whose country the journal's board page names, 4 (about 10%) are in mainland China; the countries named most often are United States (6), Australia (5) and Mainland China (4). Counted from the institutions listed on the board page; for reference only.
Which databases index International Journal of Peptide Research and Therapeutics?
According to LetPub and DOAJ records, International Journal of Peptide Research and Therapeutics is indexed in SCIE and Scopus. The journal's website also lists Embase, CAS and CAB Abstracts; that list has not been checked against each database.
Is International Journal of Peptide Research and Therapeutics open access, and what is the APC?
International Journal of Peptide Research and Therapeutics is a hybrid journal. For open-access publication: APC about USD 3,890.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .